Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

denileukin diftitox/dexamethasone

Known as: DAB389-IL2/DM 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Introduction:Denileukin diftitox, a chimeric protein, uses the cytocidal properties of diphtheria toxin to cells expressing… Expand
2008
2008
Durable complete remission of mycosis fungoides following erythroderma induced by denileukin diftitox To the Editor: Carretero… Expand
  • figure 1
  • figure 2
  • figure 1
Highly Cited
2007
Highly Cited
2007
CD4+CD25+Foxp3+ regulatory T (Treg) cells have been implicated in the lack of effective antitumor immunity. Denileukin diftitox… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
2007
2007
Denileukin diftitox (DD; Ontak, Eisai, Woodcliff Lake, NJ) is an FDA-approved targeted therapy for cutaneous T-cell lymphoma… Expand
2006
2006
BACKGROUND Denileukin diftitox, a fusion protein consisting of peptide sequences for the enzymatically active and membrane… Expand
Highly Cited
2005
Highly Cited
2005
Elimination of regulatory T lymphocytes may provide a way to break self-tolerance and unleash the anti-tumor properties of… Expand